GPER G-1 Development Group LLC is a pioneering company based in Albuquerque, NM, dedicated to developing a groundbreaking therapeutic solution for the treatment of diabetes and obesity. With approximately one third of the US population affected by these conditions, G-1 Tespria offers a revolutionary approach by modulating energy expenditure in brown fat cells, effectively targeting metabolic activity and providing a unique treatment option with minimal competition.
With the estimated economic burden of diabetes in the US surpassing $300 billion in 2017, GPER G-1 Development Group LLC aims to address this pressing issue by providing a novel therapeutic that tackles the deficiencies in insulin secretion and action. By focusing on the treatment of diabetes and obesity, G-1 Tespria has the potential to significantly improve the lives of millions of individuals and contribute to the overall well-being of society.
Generated from the website